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Objective: Clinical and animal studies have demonstrated the efﬁcacy of mesenchymal stem cell (MSC)
therapies in cartilage repair. As the efﬁcacy of many MSC-based therapies has been attributed to para-
crine secretion, particularly extracellular vesicles/exosomes, we determine here if weekly intra-articular
injections of human embryonic MSC-derived exosomes would repair and regenerate osteochondral
defects in a rat model.
Methods: In this study, osteochondral defects were created on the trochlear grooves of both distal femurs
in 12 adult rats. In each animal, one defect was treated with 100 mg exosomes and the contralateral defect
treated with phosphate buffered saline (PBS). Intra-articular injections of exosomes or PBS were
administered after surgery and thereafter weekly for a period of 12 weeks. Three unoperated age-
matched animals served as native controls. Analyses were performed by histology, immunohistochem-
istry, and scoring at 6 and 12 weeks after surgery.
Results: Generally, exosome-treated defects showed enhanced gross appearance and improved histo-
logical scores than the contralateral PBS-treated defects. By 12 weeks, exosome-treated defects displayed
complete restoration of cartilage and subchondral bone with characteristic features including a hyaline
cartilage with good surface regularity, complete bonding to adjacent cartilage, and extracellular matrix
deposition that closely resemble that of age-matched unoperated control. In contrast, there were only
ﬁbrous repair tissues found in the contralateral PBS-treated defects.
Conclusion: This study demonstrates for the ﬁrst time the efﬁcacy of human embryonic MSC exosomes in
cartilage repair, and the utility of MSC exosomes as a ready-to-use and ‘cell-free’ therapeutic alternative
to cell-based MSC therapy.
© 2016 The Author(s). Published by Elsevier Ltd on behalf of Osteoarthritis Research Society
International. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).Introduction
Adult articular cartilage has limited capacity for regeneration
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d/4.0/).and autologous chondrocyte implantation suffer issues of donor
site morbidity and often generate inferior ﬁbrocartilage repair2.
Therefore, alternative cell sources such as stem cells are being
investigated for cartilage repair2.
In recent years, advances in stem cell research have led to
promising stem cell-based therapies for cartilage repair3. Notably,
adult mesenchymal stem cells (MSCs) have been applied in labo-
ratory4,5 and clinical studies6 for cartilage repair. However, cartilage
repair by adult MSCs is not optimal5 and is hindered by limited
cellular capacity for self-renewal, proliferation and differentiation
with increasing donor age3. Human pluripotent stem cells (hPSCs)
represent a promising cell source for regenerative medicine due toesearch Society International. This is an open access article under the CC BY-NC-ND
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into various lineages, including chondrogenic lineage. However, the
clinical potential of hPSCs is hampered by issues of tumorigenicity,
genomic stability and immunogenicity7,8. As with all cell-based
therapies, there exist signiﬁcant logistic and operational chal-
lenges associated with proper handling and cell storage required to
maintain cell viability and vitality. Therefore, in view of all these
issues, there is a need to develop a strategy to overcome the dis-
advantages of a cell-based therapy.
Increasingly, the efﬁcacy of manyMSC-based therapies has been
attributed to the paracrine secretion of trophic factors, and that
exosomes play a major role in mediating tissue repair. Exosomes
are cell-secreted bi-lipid membrane, nano-sized vesicles of about
50e100 nm present in the MSC secretome9 and have been
demonstrated in recent studies to have therapeutic effects in
facilitating tissue repair in heart9, liver10 and skin11. The implication
of these ﬁndings to cartilage repair is unclear. To our knowledge,
the effect of MSC exosomes on cartilage regeneration has not been
investigated.
We hypothesized that MSC exosomes could promote osteo-
chondral regeneration. Therefore, in the setting of an established
rat osteochondral defect model12, the effects of weekly intra-
articular injections of human embryonic MSC-derived exosomes
on repair of osteochondral defects were studied.
Methods
Preparation of MSC exosomes
MSCs were derived from HuES9 human embryonic stem cells
(hESCs)13, and used for the production of MSC-conditioned me-
dium (MSC-CM). Following our established protocol, exosomes
were puriﬁed from the MSC-CM and stored at 20C until use9.
Western blotting
Western blotting was performed following standard protocol.
Brieﬂy, 20 mg proteins were separated on polyacrylamide gels,
electroblotted onto a nitrocellulose membrane and probed with
primary antibody followed by horseradish peroxidase (HRP)-
coupled secondary antibody against the primary antibody. As
described in Supplementary Table 1, the primary antibodies used
were mouse anti-human CD81, ALIX and TSG101 (Santa Cruz
Biotechnology, Dallas, TX). The labelled proteins were visualized
with ChemiDoc™ XRS imaging system using chemiluminescence.
Size determination
The size distribution of exosomes was measured by NanoSight
LM10 (Malvern,Worcestershire, UK) and analysed by Nanoparticles
Tracking Analysis software (Malvern) according to the manufac-
turer's protocol.
Detection of RNA
100 mg of exosomes were extracted for RNA using Trizol LS re-
agent and quantitated using Quanti-TTM RiboGreen RNA Assay Kit
(ThermoFisher Scientiﬁc). 200 ng exosomal RNAs were then
resolved on a 15% Novex TriseborateeEDTA (TBE)eurea gels before
staining with ethidium bromide.
Animal experiments
All procedures were performed according to the Institutional
Animal Care and Use Committee at National University of Singaporeunder protocol number: R14-913. Critical-sized osteochondral de-
fects (1.5-mm diameter and 1-mm depth) were created on troch-
lear grooves of the distal femurs of twelve 8-week-old Sprague
Dawley (SD) female rats12. The animals were randomly allocated to
two groups: defects treated with 100 mg exosomes (n ¼ 12) and
contralateral control defects treatedwith phosphate buffered saline
(PBS) vehicle (n ¼ 12). Intra-articular injections of exosomes
(100 mg exosomes per 100 ml injection) or PBS control (100 ml) were
administered after surgery and subsequently on a weekly basis.
Three unoperated animals at 12 weeks served as age-matched
native controls. Animals were allowed to move freely in the cage
after surgery with access to food and water.
Gross appearance and histological evaluation
At 6 and 12 weeks, animals were euthanized and distal femora
were resected en bloc. Gross appearance was graded by three in-
dependent blinded observers according to the International Carti-
lage Repair Society (ICRS) macroscopic assessment, including
parameters of degree of defect repair, integration to border zone
and macroscopic appearance for cartilage repair, with a maximum
score of 12. After gross examination, samples were processed for
histology. Serial sections were cut at 5-mm and stained with hae-
matoxylin and eosin (HE) and safranin-O/fast green (Saf-O).
Immunohistochemical staining for type I, II, VI and X collagens, and
lubricinwas also performed12 (Supplementary Table 1). The quality
of cartilage repair was assessed using the modiﬁed O'Driscoll his-
tologic scoring system by three blinded independent observers for
parameters including cellular morphology, matrix staining, surface
regularity, structural integrity, thickness, bonding, and freedom
from cellular changes of degeneration with a maximum score of
2714.
Statistical analysis
All quantitative data were reported as mean (95% conﬁdence
interval (CI)). Differences were determined by unpaired two-tailed
Student t test using Statview software version 5 (SAS Institute Inc.,
Cary, NC). Statistical signiﬁcance was set as P < 0.05.
Results
Characterization of MSC exosomes
The exosomes puriﬁed from MSC-CM carried exosome-
associated markers, CD81, TSG101 and ALIX as shown by western
blotting [Supplementary Fig. 1(A)]. This exosome preparation
contained homogenously sized particles with a modal size of
100 nm [Supplementary Fig. 1(B)]. It also contained RNA, most of
which are less than 300 nucleotides [Supplementary Fig. 1(C)].
Therefore, the exosome preparation used in this study qualiﬁed as
exosome as it possessed all the deﬁning characteristics of exo-
somes, a speciﬁc type of extracellular vesicles9.
Effect of MSC exosomes on repair of full-thickness cartilage defects
We assessed the effect of MSC exosomes on the repair of critical-
sized osteochondral defects in a rat model. In each animal, one
defect was treated with exosomes and the contralateral defect
treated with PBS. At 6 and 12 weeks, the distal femurs were har-
vested for analysis.
Macroscopically, all defects treated with exosomes showed
moderate to good neotissue ﬁlling, moderate surface regularity and
good integration with the host cartilage at 6 weeks. Conversely,
contralateral control defects displayed irregular surface regularity
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macroscopic assessment was 9.2 (95% CI, 6.7e11.6) in exosome-
treated defects and 8.0 (95% CI, 6.7e9.2) in the PBS-treated de-
fects, with no signiﬁcant difference [P ¼ 0.29; Fig. 1(B)].
Histologically at 6 weeks, all exosome-treated defects showed
complete neotissue ﬁlling. Four out of six exosome-treated defects
showed good surface regularity, while the remaining two defects
had a few ﬁssures on the surface. Four out of six exosome-treated
defects also showed hyaline cartilage formation characterized by
uniform distribution of high amounts of glycosaminoglycan (GAG)
and type II collagen, and low amount of type I collagen [Fig. 1(C)].
The remaining two defects demonstrated partial areal staining
(<50%) for GAG and type II collagen at a relatively lower intensity.
Under high magniﬁcation, majority of the cells (>70%) appearedFig. 1. In vivo cartilage repair at 6 weeks post-surgery. Osteochondral defects (1.5 mm diam
Exosome-treated defects were compared against the contralateral control defects treated w
represent the means ± 95% CI. P-values were determined by unpaired two-tailed Student t
staining for type II, I and VI collagens. (D) Modiﬁed O'Driscoll histologic scores for cartilag
unpaired two-tailed Student t test (n ¼ 6 per group). The results of histologic scores showe
defects at 6 weeks. Exosome treatment (100 mg per 100 ml injection on a weekly basis) indu
integration to the adjacent host cartilage. Comparatively, PBS-treated defects showed mostly
in the repair of osteochondral defects between the groups (P ¼ 0.004).chondrocytic (i.e., spherical with lacuna) and displayed pericellular
matrix staining of type VI collagen. Four out of six exosome-treated
defects further showed complete subchondral bone regeneration.
On the contrary, PBS-treated defects showed mostly ﬁbrous tissue
that stained intensely for type I collagen, but minimally for GAG
and type II collagen. Four out of six PBS-treated defects further
showed poor reconstitution of subchondral bone. At 6 weeks, the
modiﬁed O'Driscoll score revealed a signiﬁcant difference in degree
of repair: 22.5 (95% CI, 17.5e27.6) in exosome-treated group
compared to 14.0 (95% CI, 10.8e17.2) in PBS-treated group
[P ¼ 0.004; Fig. 1(D)].
At 12 weeks, the exosome-treated defects showed almost
complete neotissue coverage with good surface regularity and
complete integration with the surrounding cartilage. Conversely,eter and 1 mm depth) were created on the trochlear grooves at both knees of SD rats.
ith PBS. (A) Representative gross morphologies. (B) ICRS macroscopic scores. Values
test (n ¼ 6 per group). (C) Staining results of HE and Saf-O, and immunohistochemical
e repair at 6 weeks. Values represent means ± 95% CI. P-values were determined by
d that the defects treated with MSC exosomes produced better repair than the control
ced signiﬁcant cartilaginous neotissue with comparable matrix staining and structural
ﬁbrous and non-cartilaginous tissue. Histological scoring showed signiﬁcant difference
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plete neotissue ﬁlling, surface irregularity and distinct border areas
[Fig. 2(A)]. The ICRS macroscopic score was 9.7 (95% CI, 8.2e11.2) in
exosome-treated group and 8.6 (95% CI, 7.4e9.8) in PBS-treated
group, with no signiﬁcant difference [P ¼ 0.15; Fig. 2(B)].
Histologically, ﬁve out of six exosome-treated defects showed
smooth hyaline cartilage formation with matrix staining that was
comparable to that of native cartilage while the remaining one
defect demonstrated ﬁbrocartilaginous tissue repair. Speciﬁcally,
the exosome-treated tissues exhibited uniform and intense staining
of GAG (>80%), high level of type II collagen, and low level of type I
collagen, indicative of hyaline cartilage. Except for some areas near
the subchondral bone, exosome-treated tissues showed minimal
hypertrophy with low level of type X collagen. Under high
magniﬁcation, almost 100% of cells in the repaired tissue appeared
chondrocytic, and displayed pericellular matrix staining of type VI
collagen. Additionally, lubricin positive cells were found in the
superﬁcial and middle zones of the reparative cartilage, although aFig. 2. In vivo cartilage repair at 12 weeks post-surgery. Exosome-treated defects were com
control. (A) Representative gross morphologies. (B) ICRS macroscopic scores. Values represe
(n ¼ 6 per group). (C) Staining results of HE and Saf-O, and immunohistochemical staining
repair at 12 weeks. Values represent means ± 95% CI. P-values were determined by unpaire
group showed a new cartilage layer with good surface regularity and structural integration. T
the age-matched native cartilage. There was also complete subchondral bone regeneration.
between the groups (P < 0.001).clear zonal organization was not presented (Supplementary Fig. 2).
All exosome-repaired tissues showed good bonding to adjacent
cartilage and underlying subchondral bone. Five out of six
exosome-treated defects showed complete regeneration of sub-
chondral bone, with the exception of one defect showing partial
reconstitution (>50%) with active tissue remodelling in process
[Fig. 2(C)]. In contrast, there were only ﬁbrous tissues found in PBS-
treated defects, indicated by high amount of type I collagen, and
absence of GAG and type II collagen. Four out of six PBS-treated
defects further showed severe surface irregularity. In addition,
three out of six PBS-repaired tissues showed hypocellularity and
chondrocyte clusters (<25%), indicative of degenerative changes. At
high magniﬁcation, cells in the ﬁbrous tissue showed perfused
inter-territorial/territorial distribution of type VI collagen. At 12
weeks, the modiﬁed O'Driscoll score revealed a highly-signiﬁcant
difference in the degree of repair: 23.5 (95% CI, 20.2e26.8) for
exosome-treated group compared to 12.7 (95% CI, 11.3e14.1) in
PBS-treated group [P < 0.001; Fig. 2(D)].pared against the contralateral control defects treated with PBS and unoperated native
nt the mean ± 95% CI. P-values were determined by unpaired two-tailed Student t test
for type II, I, VI and X collagens. (D) Modiﬁed O'Driscoll histologic scores for cartilage
d two-tailed Student t test (n ¼ 6 per group). By the end of 12 weeks, exosome-treated
he regenerated neocartilage layer appeared hyaline with comparable matrix staining to
Histologic scoring showed signiﬁcant difference in the repair of osteochondral defects
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Our study demonstrates for the ﬁrst time that weekly intra-
articular administration of human embryonic MSC exosomes pro-
mote repair of critical-sized osteochondral defects in an adult
immunocompetent rat model.
Increasingly, there are supporting studies that showed the tro-
phic effects of MSCs in facilitating tissue regeneration without the
need of cellular differentiation and/or long-term engraftment9,10.
Among the trophic factors present in the secretome, exosomes play
a major role in mediating the paracrine effects of MSCs9e11.
Comparing to cellular therapies, MSC exosome therapies offer ad-
vantages of being cell-free, ready-to-use and more amenable to
reformulation to support different routes of administration.
We demonstrated in this study that weekly intra-articular in-
jections of human embryonic MSC exosomes induced an orderly
regeneration of cartilage and subchondral bone over a period of 12
weeks. The timeframe of up to 12 weeks was selected based on our
prior study where a time period of 12 weeks is sufﬁcient to observe
a full reparative response in a rat model12. By the end of 12 weeks,
defects treated with exosomes showed a good regeneration with
hyaline cartilage and underlying subchondral bone that closely
resembled that of age-matched native control, while only ﬁbrous
and non-cartilaginous tissues ﬁlled in the contralateral control
defects treated with PBS.
Previous studies demonstrated that human MSC exosomes do
not have major histocompatibility complex (MHC) class I/II pro-
teins, thereby enabling their application in immunocompetent
animals without the need for immunosuppression9e11. It has been
established that xenotransplantation of human embryonic MSCs in
immunocompetent animals for cartilage repair induces immediate
adverse tissue reaction, resulting in poor reparative outcomes8. In
this study, no adverse inﬂammatory response was observed in all
animals, supporting the potential application of human MSC exo-
somes in allogeneic human recipients.
We have previously showed that MSC exosomes contain many
regulatory components including microRNAs (miRNAs), mRNAs,
and proteins that are likely to be mediators in cellecell commu-
nications to induce changes in cell functions and processes15.
Although the exact component(s) is yet to be elucidated, it is
plausible that a myriad of components present in the MSC exo-
somes are needed to orchestrate tissue regeneration including
cartilage and bone repair in this instance. Nevertheless, future
studies would need to dissect the components present in MSC
exosomes and to investigate their underlying mechanisms in
cartilage repair.
Collectively, this proof-of-concept study demonstrates a ready-
to-use and ‘cell-free’ strategy of utilizing human embryonic MSC
exosomes for cartilage repair, that greatly overcome the impeding
limitations of current cell-based therapies.Author contributions
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